J&J: promising data for Tecvayli in myeloma

(CercleFinance.com) - Johnson & Johnson announces promising data on Tecvayli from two studies (MajesTEC-5 and MajesTEC-4), presented at ASH 2024.


These trials explore the use of Tecvayli in patients with newly diagnosed multiple myeloma (NDMM), and highlight promising efficacy and a tolerable safety profile.

These data were presented orally at the American Society of Hematology (ASH) 2024 Annual Meeting.

According to Rachel Kobos, VP Oncology R&D, these results reinforce the potential of combinations involving Tecvayli to improve multiple myeloma treatments.

Copyright (c) 2024 CercleFinance.com. All rights reserved.